In order to assess the clinical implications of hereditary F XII deficietrcy, all available members of Swiss families with F XII deficiency were investigated. Based on the F XII: C values and the family pedigree, the 74 subjects, aged 8-–82 years, were classified as homozygotes/double heterozygotes for F XII deficiency (n = 18), as obligatory (n = 20) or possibly (n = 25) heterozygotes, respectively, and as norrnals (n = 11). None of the 18 subjects with F XII: C <0.01 U/ml and only one possibly heterozygous woman had an abnormal bleeding tendency, confirming the notion that Hageman trait generally does not result in a hemorrhagic diathesis. Two of the 18 subjects with severe F XII deficiency had suffered from venous thromboembolic disease at age <40 years. One heterozygous woman had a leg ulcer probably due to venous thrombosis. Thus, whereas homozygous F XII deficiency may be associated with an increased risk for venous thromboembolic disease, partial F XII deficiency is not, by itself, a strong risk factor for thrombosis.
Where as 17 of the 18 subjects with F xII : C <0.01 U/ml had no detectable F XIL Ag, one cross reacting material-positive F XII deficient subject (F XII:Ag = 0.11 U/ml) was identified. The dysfunctional F XII, present in this subject's plasma and tentatively called F XII Bern, is the fourth abnormal F XII molecule identified so far.
References
1
Ratnoff OD,
Colopy JE.
Familial hemorrhagic trait associated with deficiency of clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-613
7
Bouma BN,
Miles LA,
Beretta G,
Griffin JH.
Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry 1980; 19: 1151-1160
8
Griffin JH,
Cochrane CG.
Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci (USA) 1976; 73: 2554-2558
9
Meier HL,
Pierce JV,
Colman RW,
Kaplan AP.
Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. J Clin Invest 1977; 60: 18-31
16
Haanen C,
Hommes F,
Benraad H,
Morselt G.
A case of Hageman-factor deficiency and a method to purify the factor. Thromb Diath Haemorrh 1960; 5: 201-207
23
Baumann R,
Straub PW.
Congenital deficiency of Hageman factor (clotting factor XII). Report on the first two families found in Switzerland. Helv Med Acta 1968; 34: 313-326
26
Hellstern P,
Kohler M,
Schmengler K,
Doenecke P,
Wenzel E.
Arterial and venous thrombosis and normal response to streptokinase treatment in a young patient with severe Hageman factor deficiency. Acta Haematol 1983; 69: 123-126
27
Lodi S,
Isa L,
Pollini E,
Ferrari BravoA,
Scalvini A.
Defective intrinsic fibrinolytic activity in a patient with severe factor XII deficiency and myocardial infarction. Scand J Haematol 1984; 33: 80-82
30
Vergnes C,
Lorient-Roudaut MF,
Haissaguerre M,
Roudaut R,
Wicker P,
Boisseau MR,
Dallocchio M.
Thrombophlebites et embolies pulmonaires lors d’un deficit congenital en facteur XII. Arch Mai Coeur 1985; 78: 440-443
31
Goodnough LT,
Saito H,
Ratnoff OD.
Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: A report of 21 patients and a review of 50 previously reported cases. Medicine 1983; 62: 248-255
32
Mannhalter C,
Fischer M,
Hopmeier P,
Deutsch E.
Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1: 259-263
34
Weiss HJ,
Turitto VT,
Vicic WJ,
Baumgartner HR.
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: Greater in factor XII and XI than in factor VIII and IX deficiency. Blood 1984; 63: 1004-1014
35
Thommen D,
Sulzer I,
Buhrfeind E,
Naef R,
Furlan M,
Lammle B.
Messung der Blutungszeit und Untersuchung der Thrombozy-tenaggregation. Standardisierung der Methoden, Normalwerte und Resultate bei Patienten mit Verdacht auf hamorrhagische Diathese. Schweiz Med Wschr 1988; 118: 1559-1567
37
Lammle B,
Berrettini M,
Griffin JH.
Enhanced specificity of immunoblotting using radiolabeled antigen overlay. Studies of blood coagulation factor XII and prekallikrein in plasma. Anal Biochem 1986; 156: 118-125
38
Thommen D,
Buhrfeind E,
Felix R,
Sulzer I,
Furlan M,
Lammle B.
Hamostaseparameter bei 55 Patienten mit venosen und/oder arteriel-len Thromboembolien. Schweiz Med Wschr 1989; 119: 493-499
39
Passing H,
Bablok W.
A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. J Clin Chem Clin Biochem 1983; 21: 709-720
41
Saito H,
Scott JG,
Movat HZ,
Scialla SJ.
Molecular heterogeneity of Hageman trait (factor XII deficiency). Evidence that two of 49 subjects are cross-reacting material positive (CRM+). J Lab Clin Med 1979; 94: 256-265
42
Berrettini M,
Lammle B,
Ciavarella G,
Ciavarella N.
Functional and immunological studies of abnormal factor XII in a cross reacting material positive (CRM+) factor XII deficiency. Thromb Haemostas 1985; 54: 120 (Abstract).